Correction to: J Exp Clin Cancer Res 38, 299 (2019)
https://doi.org/10.1186/s13046-019-1185-0
Anzeige
Following publication of the original article [1], minor errors were discovered in Figs. 1 and 4; specifically:
Fig. 1c: an image from the PD-1R group was incorrectly used for a representative picture the Control group; the top right image has now been corrected
Fig. 4b: the top two flow cytometry panels were duplicated in error; the top right panel has now been corrected
Fig. 1
PD-1 blockade resistance occurred in the oral malignant transformation mouse model. a The schematic picture shows the 4NQO treatment and anti-PD-1 antibody(n = 23) and control IgG (vehicle control, n = 5) drug delivery strategies in C57BL/6 mice. b Body weight (g) was measured and documented for the control group and anti-PD-1 group (the PD-1R and PD-1S groups) once a week. Significant weight loss was observed in the PD-1R group at week 20. The data are presented as the mean ± SEM (one-way repeated-measures ANOVA, *P < 0.05, **P < 0.01). c Representative macroscopic observation of the lingual mucosal lesions after treatment with control IgG (left panel) or anti-PD-1 antibody in the PD-1R group (middle panel) and PD-1S group (right panel). For PD-1R group, similarly with control group, leukoplakia-like lesions with smooth surfaces progressed into white masses with cauliflower-like (upper left), rough and granular (upper right) or exogenous verrucous surfaces (lower right and left). The lingual mucosal lesions treated with anti-PD-1 antibodies maintained a wrinkled paper-like appearance macroscopically in PD-1S group. d Representative hematoxylin and eosin (H&E) staining of dysplasia, carcinoma in situ (pre-invasive carcinoma) and invasive carcinoma. Statistical significance was determined by the Kruskal-Wallis test, *P < 0.05
Fig. 4
Relative distributions of key immunosuppressive cells after the anti-PD-1 antibody treatment. a, b Flow cytometry analysis was performed to characterize and quantify Tregs (CD4+Foxp3+) and MDSCs (CD11b+Gr-1+). Compared to the PD-1S group, the PD-1R group exhibited an increase in Treg accumulation. All data represent the mean ± SEM. Statistical significance was determined by Student’s t test, *P < 0.05. Tregs, regulatory T cells; MDSCs, myeloid-derived suppressor cells
×
×
The corrected figures are given here. The correction does not have any effect on the final conclusions of the paper.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.
In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.
Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.
Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
